Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22731686 | 1.00 | MEN1 (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL25467053 | 1.00 | MEN1 (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1279722 | 0.91 | HPGD (0.48) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL344569 | 0.91 | HPGD (0.48) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL344797 | 0.91 | HPGD (0.48) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1992277 | 0.86 | MEN1 (0.52) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL192730 | 0.86 | MEN1 (0.52) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL641613 | 0.86 | MEN1 (0.52) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL23034653 | 0.85 | MEN1 (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL6915624 | 0.84 | NR1H2 (0.50) | MEN1ALDH1A1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025026392-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| CN-114502540-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3889154-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| EP-2683716-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | Glaxo Group Limited (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-20140005188-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-01-02 | — | — | US | disclosed |
| WO-2012123312-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123312-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| WO-2007115077-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005188-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | MEN1 3382/4885ALDH1A1 2833/4885MAPT 3206/4885 |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | MEN1 3345/4885ALDH1A1 1006/4885MAPT 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.